Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number: 001-41160 ALLARITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter ...

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment Exhibit 99.1 Cash and restricted cash balance of approximately $27 million at end of Q1 2025, reinforcing financial stability TARPON SPRINGS, Fla., May 9, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today re ...

- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months- Initiated utilization of share repurchase program- Cash and restricted cash balance of approximately $27 million at end of Q1 2025, reinforcing financial stability TARPON SPRINGS, Fla., May 9, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing sten ...

TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology today announced the presentation of a poster containing data on a new DRP for the monoclonal antibody drug daratumumab. The post ...

Exhibit 99.1 Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027 - Strengthened cash position expected to support the Company through first substantive data readout in its Phase 2 ovarian cancer trial, with enrollment scheduled to begin H1 2025 - Enrollment in new Phase 2 SCLC trial to begin in Q2-Q3 2025, fully funded by ...

Boston (March 31, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP/WNT pathway inhibitor—today announced financial results for the year ended December 31, 2024, and provided a general business update. Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, stated: "2024 was a transformational year for Allarity as we made significant progress in advancing sten ...

Core Viewpoint - Allarity Therapeutics has engaged Shareholder Intelligence Services to investigate potential illegal naked short selling and trading irregularities in its stock, emphasizing its commitment to protecting shareholder value and ensuring fair trading practices [1][2][3]. Group 1: Engagement with ShareIntel - The collaboration with ShareIntel aims to monitor trading activities and detect unusual short-selling patterns, utilizing ShareIntel's DRIL-Down™ technology for compliance-driven data analytics [2][3]. - Allarity will take corrective actions, including legal recourse if necessary, based on the findings from ShareIntel's investigation [2][3]. Group 2: CEO's Statement - The CEO of Allarity highlighted the importance of this engagement in fostering market confidence and addressing notable stock volatility observed by the company [3]. - The company aims to ensure that its shares are traded fairly and free from manipulation as it advances the clinical development of stenoparib [3]. Group 3: About Stenoparib - Stenoparib is a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential as a therapeutic for various cancers, particularly ovarian cancer [4]. - The drug's unique mechanism involves inhibiting PARP and blocking Wnt pathway activation, which is significant in cancer progression [4]. Group 4: Company Overview - Allarity Therapeutics is focused on developing personalized cancer treatments and has secured exclusive global rights for the development and commercialization of stenoparib [5]. - The company utilizes its DRP technology to create companion diagnostics aimed at selecting patients who would benefit most from stenoparib [5].

Core Viewpoint - The Schall Law Firm is investigating Allarity Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information [1][2]. Group 1: Investigation Details - The investigation centers on whether Allarity issued false or misleading statements and failed to disclose relevant information to investors [2]. - Allarity filed a Form 8-K with the SEC on July 22, 2024, indicating that it received a "Wells Notice" from the SEC regarding its disclosures related to meetings with the FDA concerning its New Drug Application for Dovitinib [2]. - The Wells Notice also indicated that three former officers of Allarity received similar notices from the SEC, and the SEC staff has made a preliminary determination to recommend enforcement action against the Company for alleged violations of federal securities laws [2].

Core Insights - Allarity Therapeutics presented new clinical data for stenoparib, a dual PARP/Wnt pathway inhibitor, at the SGO 2025 Annual Meeting, highlighting its potential in treating advanced ovarian cancer [1][2] Group 1: Clinical Trial Findings - The Phase 2 trial of stenoparib involved patients with advanced, recurrent ovarian cancer who had undergone three or more lines of therapy, with a focus on those with platinum-resistant disease [3][4] - Among the 15 enrolled patients, 14 were platinum-resistant, and one was primary platinum-refractory, with limited effective treatment options available [3] - Notably, one patient achieved a confirmed complete response lasting over 10 months, and two patients remain on therapy for more than 17 months [3][4] Group 2: Unique Mechanism and Patient Benefit - Stenoparib demonstrated clinical benefits in patients without BRCA mutations, indicating its unique dual action in inhibiting both PARP and the Wnt pathway [4][8] - The study is the first to dose stenoparib twice daily, optimizing the inhibition of PARP and Tankyrase, and showing potential durable clinical benefits in heavily pre-treated patients [8][9] Group 3: Future Directions and Company Strategy - The results from the exploratory Phase 2 study are foundational for Allarity, supporting the development of a new protocol to evaluate stenoparib in platinum-resistant patients [9][12] - Allarity is committed to addressing unmet medical needs in cancer treatment, focusing on personalized therapies and the development of companion diagnostics for stenoparib [11][12]

Core Viewpoint - The Schall Law Firm is investigating Allarity Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information [1][2]. Group 1: Investigation Details - The investigation centers on whether Allarity issued false or misleading statements and failed to disclose relevant information to investors [2]. - Allarity filed a Form 8-K with the SEC on July 22, 2024, indicating that it received a "Wells Notice" from the SEC regarding its disclosures related to meetings with the FDA concerning its New Drug Application for Dovitinib [2]. - The Wells Notice also indicated that three former officers of Allarity received similar notices from the SEC, suggesting a broader issue within the company's management [2]. Group 2: SEC Actions - The Wells Notice informed Allarity that the SEC staff has made a preliminary determination to recommend an enforcement action against the company for alleged violations of federal securities laws [2].